These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

528 related items for PubMed ID: 16740764

  • 1. Phase II study of docetaxel and S-1 combination therapy for advanced or recurrent gastric cancer.
    Yoshida K, Ninomiya M, Takakura N, Hirabayashi N, Takiyama W, Sato Y, Todo S, Terashima M, Gotoh M, Sakamoto J, Nishiyama M.
    Clin Cancer Res; 2006 Jun 01; 12(11 Pt 1):3402-7. PubMed ID: 16740764
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Phase I study of combination therapy with S-1 and docetaxel (TXT) for advanced or recurrent gastric cancer.
    Yoshida K, Hirabayashi N, Takiyama W, Ninomiya M, Takakura N, Sakamoto J, Nishiyama M, Toge T.
    Anticancer Res; 2004 Jun 01; 24(3b):1843-51. PubMed ID: 15274365
    [Abstract] [Full Text] [Related]

  • 5. Phase II study of biweekly docetaxel and S-1 combination therapy for advanced or recurrent gastric cancer.
    Kakeji Y, Oki E, Egashira A, Sadanaga N, Takahashi I, Morita M, Emi Y, Maehara Y.
    Oncology; 2009 Jun 01; 77(1):49-52. PubMed ID: 19556809
    [Abstract] [Full Text] [Related]

  • 6. Phase II study of S-1, docetaxel and cisplatin combination chemotherapy in patients with unresectable metastatic gastric cancer.
    Sato Y, Takayama T, Sagawa T, Takahashi Y, Ohnuma H, Okubo S, Shintani N, Tanaka S, Kida M, Sato Y, Ohta H, Miyanishi K, Sato T, Takimoto R, Kobune M, Yamaguchi K, Hirata K, Niitsu Y, Kato J.
    Cancer Chemother Pharmacol; 2010 Sep 01; 66(4):721-8. PubMed ID: 20041328
    [Abstract] [Full Text] [Related]

  • 7. A multicenter phase II study of combined chemotherapy with docetaxel, cisplatin, and S-1 in patients with unresectable or recurrent gastric cancer (KDOG 0601).
    Koizumi W, Nakayama N, Tanabe S, Sasaki T, Higuchi K, Nishimura K, Takagi S, Azuma M, Ae T, Ishido K, Nakatani K, Naruke A, Katada C.
    Cancer Chemother Pharmacol; 2012 Feb 01; 69(2):407-13. PubMed ID: 21796483
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Phase I study of combination therapy with S-1 and weekly docetaxel for advanced gastric cancer.
    Ozaki T, Tamura K, Satoh T, Kurata T, Shimizu T, Miyazaki M, Okamoto I, Nakagawa K, Fukuoka M.
    Anticancer Res; 2007 Feb 01; 27(4C):2657-65. PubMed ID: 17695429
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. A phase II study of neoadjuvant combination chemotherapy with docetaxel, cisplatin, and S-1 for locally advanced resectable gastric cancer: nucleotide excision repair (NER) as potential chemoresistance marker.
    Hirakawa M, Sato Y, Ohnuma H, Takayama T, Sagawa T, Nobuoka T, Harada K, Miyamoto H, Sato Y, Takahashi Y, Katsuki S, Hirayama M, Takahashi M, Ono M, Maeda M, Takada K, Hayashi T, Sato T, Miyanishi K, Takimoto R, Kobune M, Hirata K, Kato J.
    Cancer Chemother Pharmacol; 2013 Mar 01; 71(3):789-97. PubMed ID: 23338051
    [Abstract] [Full Text] [Related]

  • 16. A phase II study of docetaxel and cisplatin in patients with gastric cancer recurring after or progressing during 5-FU/platinum treatment.
    Kim H, Park JH, Bang SJ, Kim DH, Cho HR, Kim GY, Min YJ.
    Jpn J Clin Oncol; 2005 Dec 01; 35(12):727-32. PubMed ID: 16332720
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. A randomized phase 2 study of docetaxel and S-1 versus docetaxel and cisplatin in advanced gastric cancer with an evaluation of SPARC expression for personalized therapy.
    Jeung HC, Rha SY, Im CK, Shin SJ, Ahn JB, Yang WI, Roh JK, Noh SH, Chung HC.
    Cancer; 2011 May 15; 117(10):2050-7. PubMed ID: 21523716
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 27.